United Therapeutics CEO Martine Rothblatt Exercises & Sells 9,500 Shares Under 10b5-1 Plan

Executive Summary

On September 8, 2026, Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp ($UTHR), executed a pre-arranged transaction involving the exercise of stock options and the subsequent sale of 9,500 shares of common stock. The transactions were completed pursuant to a Rule 10b5-1 trading plan established on November 7, 2025.

Transaction Details

• Derivative Exercise: Exercised 9,500 stock options with an exercise price of $117.76 per share (expiring March 15, 2027).
• Open Market Dispositions: Sold a total of 9,500 shares across multiple tranches at weighted average prices ranging from $481.91 to $504.15 per share, yielding aggregate gross proceeds of approximately $4.74 million (average realized price of ~$499.03 per share).
• Post-Transaction Holdings: Following these sales, the trust holds 324,443 shares of Common Stock indirectly, alongside additional direct holdings of 40,513 shares, other family trust holdings, and 480,410 remaining stock options.

Analysis & Significance

Because this transaction represents an exercise and sale under an established Rule 10b5-1 plan adopted in November 2025, it reflects programmatic execution rather than a discretionary market signal. The trading significance is rated as Low due to the pre-scheduled nature of the trades and substantial remaining equity exposure held by the insider.